Free Trial
→ Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free MGRX Stock Alerts

Mangoceuticals (MGRX) Financials

Mangoceuticals logo
$0.16 -0.03 (-14.05%)
As of 12:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Mangoceuticals

Annual Income Statements for Mangoceuticals

This table shows Mangoceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.00 -9.21 -9.51 -22
Consolidated Net Income / (Loss)		 -2.00 -9.21 -8.71 -21
Net Income / (Loss) Continuing Operations		 -2.00 -9.21 -8.71 -21
Total Pre-Tax Income 		-2.00 -9.21 -8.71 -21
Total Operating Income		 -1.99 -9.22 -7.97 -18
Total Gross Profit		 0.00 0.43 0.38 0.25
Total Revenue		 0.01 0.73 0.62 0.46
Operating Revenue		 0.01 0.73 0.62 0.46
Total Cost of Revenue		 0.00 1.13 1.16 1.40
Operating Cost of Revenue		 0.00 1.13 1.16 1.40
Total Operating Expenses		 2.00 8.82 8.15 18
Selling, General & Admin Expense		 1.64 3.32 3.00 3.76
Marketing Expense		 0.35 2.10 1.48 0.82
Amortization Expense		 - - 0.72 1.12
Other Operating Expenses / (Income)		 0.00 3.40 2.95 13
Total Other Income / (Expense), net		 -0.01 0.01 -0.01 -1.49
Interest Expense		 0.01 -0.01 0.01 0.12
Other Income / (Expense), net		 0.00 0.00 0.00 -1.37
Income Tax Expense		 0.00 0.00 0.00 0.00
Preferred Stock Dividends Declared		 - - 0.80 1.18
Net Income / (Loss) Attributable to Noncontrolling Interest		 - 0.00 -0.00 -0.00
Basic Earnings per Share		 ($0.19) ($8.58) ($4.80) ($2.17)
Weighted Average Basic Shares Outstanding		 10.80M 1.07M 1.98M 10.07M
Diluted Earnings per Share		 ($0.19) ($8.58) ($4.80) ($2.17)
Weighted Average Diluted Shares Outstanding		 10.80M 1.07M 1.98M 10.07M
Weighted Average Basic & Diluted Shares Outstanding		 - - 5.17M 16.97M

Quarterly Income Statements for Mangoceuticals

This table shows Mangoceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.74 -2.37 -2.39 -2.29 -2.46 -5.13 -5.71 -7.91 -3.65 -3.70 -1.61
Consolidated Net Income / (Loss)		 -2.57 -2.37 -2.39 -2.00 -1.95 -4.84 -5.42 -7.62 -2.77 -3.40 -1.31
Net Income / (Loss) Continuing Operations		 -3.74 -2.37 -2.39 -2.00 -1.95 -4.84 -5.42 -7.62 -2.77 -3.40 -1.31
Total Pre-Tax Income 		-2.57 -2.37 -2.39 -2.00 -1.95 -4.84 -5.42 -7.62 -2.77 -3.40 -1.31
Total Operating Income		 -2.57 -2.37 -2.17 -1.76 -1.68 -4.58 -5.27 -7.54 -0.37 -3.13 -1.03
Total Gross Profit		 0.14 0.15 0.07 0.08 0.08 0.06 0.09 0.05 0.05 0.03 0.04
Total Revenue		 0.24 0.21 0.16 0.13 0.11 0.11 0.17 0.08 0.09 0.07 0.07
Operating Revenue		 0.24 0.21 0.16 0.13 0.11 0.11 0.17 0.08 0.09 0.07 0.07
Total Cost of Revenue		 0.19 0.31 0.29 0.26 0.29 0.02 0.65 0.54 -0.44 0.01 0.44
Operating Cost of Revenue		 0.19 0.31 0.29 0.26 0.29 0.02 0.65 0.54 -0.44 0.01 0.44
Total Operating Expenses		 3.79 2.27 2.04 1.63 2.21 4.66 4.79 7.08 2.03 3.19 0.66
Selling, General & Admin Expense		 2.08 0.77 0.85 0.52 0.85 1.54 1.25 0.31 0.66 1.05 0.26
Marketing Expense		 0.30 0.85 0.23 0.25 0.15 0.28 0.26 0.10 0.18 0.09 0.30
Other Operating Expenses / (Income)		 1.42 0.64 0.96 0.85 0.49 2.84 3.29 6.67 0.07 2.04 0.11
Total Other Income / (Expense), net		 -0.01 0.00 -0.22 -0.24 0.45 -0.26 -0.15 -0.15 -1.22 -0.28 -0.28
Interest Expense		 - 0.00 0.22 0.24 -0.45 -0.01 0.15 0.08 -0.09 0.00 0.00
Other Income / (Expense), net		 - 0.00 - - - -0.28 0.00 -0.08 - -0.28 -0.28
Income Tax Expense		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Preferred Stock Dividends Declared		 - - - 0.29 - 0.29 0.29 0.29 - 0.29 0.29
Net Income / (Loss) Attributable to Noncontrolling Interest		 - -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 0.00 0.00 -0.00
Basic Earnings per Share		 ($3.48) ($1.50) ($1.37) ($1.14) ($1.24) ($1.12) ($0.57) ($0.69) ($0.36) ($0.22) ($0.09)
Weighted Average Basic Shares Outstanding		 1.07M 1.57M 1.74M 2.01M 1.98M 4.59M 9.98M 11.52M 10.07M 16.48M 17.12M
Diluted Earnings per Share		 ($3.48) ($1.50) ($1.37) ($1.14) ($1.24) ($1.12) ($0.57) ($0.69) ($0.36) ($0.22) ($0.09)
Weighted Average Diluted Shares Outstanding		 1.07M 1.57M 1.74M 2.01M 1.98M 4.59M 9.98M 11.52M 10.07M 16.48M 17.12M
Weighted Average Basic & Diluted Shares Outstanding		 0.00 24.82M 29.91M 2.49M 5.17M 11.03M 10.54M 13.91M 16.97M 17.17M 21.57M

Annual Cash Flow Statements for Mangoceuticals

This table details how cash moves in and out of Mangoceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.66 0.06 -0.67 1.42
Net Cash From Operating Activities		 -1.35 -7.00 -4.86 -5.85
Net Cash From Continuing Operating Activities		 -1.35 -7.06 -4.86 -5.85
Net Income / (Loss) Continuing Operations		 -2.00 -9.21 -8.71 -21
Consolidated Net Income / (Loss)		 -2.00 -9.21 -8.71 -21
Depreciation Expense		 0.00 0.02 0.01 0.00
Amortization Expense		 - - 0.72 1.72
Non-Cash Adjustments To Reconcile Net Income		 0.64 2.15 2.38 13
Changes in Operating Assets and Liabilities, net		 0.01 -0.01 0.73 -0.18
Net Cash From Investing Activities		 -0.04 -0.00 0.07 0.00
Net Cash From Continuing Investing Activities		 -0.04 -0.00 0.07 0.00
Sale of Property, Plant & Equipment		 - 0.00 0.07 0.00
Net Cash From Financing Activities		 2.05 7.06 4.13 7.27
Net Cash From Continuing Financing Activities		 2.05 7.06 4.13 7.27
Repayment of Debt		 -0.03 -0.09 0.00 -0.21
Issuance of Debt		 0.08 -0.08 0.15 0.68
Issuance of Preferred Equity		 - 0.00 2.65 0.10
Issuance of Common Equity		 2.00 6.20 1.33 4.63
Other Financing Activities, net		 - 1.02 0.00 2.08
Cash Interest Paid		 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Mangoceuticals

This table details how cash moves in and out of Mangoceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -0.50 -0.72 0.48 -0.42 -0.01 0.02 0.02 0.38 1.01 -1.31 0.06
Net Cash From Operating Activities		 -1.70 -0.99 -1.58 -1.17 -1.13 -2.27 -1.26 -1.24 -1.08 -1.31 -0.26
Net Cash From Continuing Operating Activities		 -1.76 -0.99 -1.58 -1.17 -1.13 -2.26 -1.27 -1.24 -1.08 -1.31 -0.26
Net Income / (Loss) Continuing Operations		 -2.57 -2.37 -2.39 -2.00 -1.95 -4.84 -5.42 -7.62 -2.77 -3.40 -1.31
Consolidated Net Income / (Loss)		 -2.57 -2.37 -2.39 -2.00 -1.95 -4.84 -5.42 -7.62 -2.77 -3.40 -1.31
Depreciation Expense		 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Amortization Expense		 - - - 0.21 0.26 0.41 0.84 0.02 0.45 0.29 0.29
Non-Cash Adjustments To Reconcile Net Income		 0.79 0.45 0.85 0.64 0.44 2.00 3.24 6.74 1.27 1.70 0.10
Changes in Operating Assets and Liabilities, net		 0.02 0.92 -0.29 -0.02 0.12 0.16 0.07 -0.38 -0.02 0.10 0.66
Net Cash From Financing Activities		 1.20 0.27 1.99 0.75 1.12 2.29 1.28 1.62 2.08 0.00 0.32
Net Cash From Continuing Financing Activities		 1.20 0.27 1.99 0.75 1.12 2.29 1.28 1.62 2.08 0.00 0.32
Issuance of Common Equity		 1.20 0.18 0.39 - 0.76 0.66 0.43 1.32 2.21 0.00 0.27

Annual Balance Sheets for Mangoceuticals

This table presents Mangoceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.00 1.05 15 16
Total Current Assets		 0.69 0.84 0.08 1.55
Cash & Equivalents		 0.68 0.74 0.06 1.49
Accounts Receivable		 - - 0.00 0.02
Prepaid Expenses		 0.01 0.06 0.00 0.01
Other Current Assets		 - 0.02 0.02 0.03
Plant, Property, & Equipment, net		 0.12 0.10 0.00 0.00
Total Noncurrent Assets		 0.19 0.12 15 15
Intangible Assets		 - 0.00 15 14
Other Noncurrent Operating Assets		 0.19 0.12 0.06 0.31
Total Liabilities & Shareholders' Equity		 1.00 1.05 15 16
Total Liabilities		 0.39 0.28 1.43 0.89
Total Current Liabilities		 0.26 0.21 1.43 0.89
Short-Term Debt		 0.17 0.00 0.15 0.00
Accounts Payable		 0.03 0.14 0.84 0.42
Accrued Expenses		 - 0.01 - 0.00
Current Deferred & Payable Income Tax Liabilities		 0.00 - 0.00 0.01
Other Current Liabilities		 0.06 0.06 0.44 0.46
Total Noncurrent Liabilities		 0.13 0.06 0.00 0.00
Other Noncurrent Operating Liabilities		 0.13 0.06 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.61 0.77 14 15
Total Preferred & Common Equity		 0.61 0.77 14 15
Preferred Stock		 - 0.00 0.00 0.00
Total Common Equity		 0.61 0.77 14 15
Common Stock		 2.63 12 34 56
Retained Earnings		 -2.02 -11 -20 -41
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.01 -0.00
Other Equity Adjustments		 - - 0.32 0.32
Noncontrolling Interest		 - 0.00 -0.00 -0.00

Quarterly Balance Sheets for Mangoceuticals

This table presents Mangoceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 1.60 0.30 15 15 22 21 17 14 14
Total Current Assets		 1.34 0.09 0.52 0.10 0.18 0.12 0.60 0.21 0.25
Cash & Equivalents		 1.24 0.02 0.49 0.07 0.08 0.10 0.48 0.17 0.23
Accounts Receivable		 - - - - - - - 0.02 0.00
Prepaid Expenses		 0.08 0.06 0.01 0.00 0.08 - 0.10 0.00 0.00
Other Current Assets		 - - - 0.02 0.02 0.02 0.02 0.02 0.02
Plant, Property, & Equipment, net		 0.10 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.15 0.12 15 15 22 21 16 14 14
Intangible Assets		 - - 15 15 22 21 16 14 14
Other Noncurrent Operating Assets		 0.15 0.12 0.11 0.07 0.04 0.03 0.01 0.29 0.28
Total Liabilities & Shareholders' Equity		 1.60 0.30 15 15 22 21 17 14 14
Total Liabilities		 0.24 1.26 1.41 1.40 1.50 1.60 0.80 0.97 1.65
Total Current Liabilities		 0.16 1.21 1.38 1.39 1.50 1.60 0.80 0.74 1.40
Short-Term Debt		 0.00 0.09 0.19 0.19 0.00 0.60 0.10 - 0.04
Accounts Payable		 0.09 1.05 0.72 0.75 1.18 0.77 0.53 0.53 0.89
Accrued Expenses		 - - - 0.01 - 0.03 - - 0.01
Other Taxes Payable		 0.01 0.01 - - - - - 0.00 0.01
Other Current Liabilities		 0.06 0.07 0.47 0.44 0.33 0.20 0.17 0.20 0.45
Total Noncurrent Liabilities		 0.08 0.05 0.03 0.01 0.00 0.00 0.00 0.24 0.25
Other Noncurrent Operating Liabilities		 0.08 0.05 0.03 0.01 0.00 0.00 0.00 0.24 0.25
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1.35 -0.96 14 13 20 19 16 13 13
Total Preferred & Common Equity		 1.35 -0.96 14 13 20 19 16 13 13
Preferred Stock		 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1.35 -0.96 14 13 20 19 16 13 13
Common Stock		 10 13 29 31 46 51 53 57 58
Retained Earnings		 -8.66 -14 -16 -18 -26 -32 -38 -44 -45
Accumulated Other Comprehensive Income / (Loss)		 - -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.01
Other Equity Adjustments		 - - 0.51 - 0.32 0.32 0.32 0.32 0.32
Noncontrolling Interest		 - -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00

Annual Metrics And Ratios for Mangoceuticals

This table displays calculated financial ratios and metrics derived from Mangoceuticals' official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 17,039,500.00 2,486,512.00 13,906,570.00
DEI Adjusted Shares Outstanding		 0.00 1,135,967.00 2,486,512.00 13,906,570.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -8.11 -3.82 -1.57
Growth Metrics		 - - - -
Revenue Growth		 0.00% 8,083.16% -15.81% -25.96%
EBITDA Growth		 0.00% -362.54% 21.25% -144.09%
EBIT Growth		 0.00% -362.89% 13.53% -143.33%
NOPAT Growth		 0.00% -362.89% 13.53% -126.20%
Net Income Growth		 0.00% -361.07% 5.48% -137.08%
EPS Growth		 0.00% -361.07% 44.06% 54.79%
Operating Cash Flow Growth		 0.00% -419.66% 30.49% -20.28%
Free Cash Flow Firm Growth		 0.00% 0.00% -206.42% 37.19%
Invested Capital Growth		 0.00% -63.76% 39,164.84% -2.31%
Revenue Q/Q Growth		 0.00% 0.00% -18.43% -2.33%
EBITDA Q/Q Growth		 0.00% -41,033.18% 18.15% 0.76%
EBIT Q/Q Growth		 0.00% 0.00% 10.05% -0.29%
NOPAT Q/Q Growth		 0.00% 0.00% 10.05% 6.77%
Net Income Q/Q Growth		 0.00% 0.00% 6.64% -4.14%
EPS Q/Q Growth		 0.00% 0.00% 10.45% -26.16%
Operating Cash Flow Q/Q Growth		 0.00% -17.62% 10.46% 0.88%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.03% 20.05%
Invested Capital Q/Q Growth		 0.00% -69.72% 3.96% -10.64%
Profitability Metrics		 - - - -
Gross Margin		 54.26% 58.99% 61.70% 54.91%
EBITDA Margin		 -22,236.48% -1,256.88% -1,175.65% -3,875.64%
Operating Margin		 -22,279.70% -1,260.28% -1,294.42% -3,954.28%
EBIT Margin		 -22,279.70% -1,260.28% -1,294.42% -4,253.73%
Profit (Net Income) Margin		 -22,352.11% -1,259.40% -1,413.80% -4,526.87%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.33% 99.93% 109.22% 106.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1,413.47% -9,604.58% -79.31% -90.98%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,296.29% -9,164.66% 886.27% 1,058.97%
Return on Net Nonoperating Assets (RNNOA)		 1,088.07% 8,277.89% -39.00% -50.69%
Return on Equity (ROE)		 -325.40% -1,326.69% -118.31% -141.67%
Cash Return on Invested Capital (CROIC)		 0.00% -9,510.99% -278.30% -88.64%
Operating Return on Assets (OROA)		 -198.51% -897.62% -97.09% -123.32%
Return on Assets (ROA)		 -199.15% -896.99% -106.05% -131.24%
Return on Common Equity (ROCE)		 -325.40% -1,326.69% -118.31% -141.68%
Return on Equity Simple (ROE_SIMPLE)		 -325.40% -1,189.08% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.39 -6.45 -5.58 -13
NOPAT Margin		 -15,595.79% -882.20% -906.10% -2,768.00%
Net Nonoperating Expense Percent (NNEP)		 -117.18% -439.92% -965.58% -1,149.94%
Return On Investment Capital (ROIC_SIMPLE)		 - -832.94% -39.59% -83.05%
Cost of Revenue to Revenue		 45.74% 154.86% 187.88% 307.55%
SG&A Expenses to Revenue		 18,386.53% 453.79% 487.21% 823.73%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 22,333.95% 1,205.42% 1,323.70% 3,992.92%
Earnings before Interest and Taxes (EBIT)		 -1.99 -9.22 -7.97 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.99 -9.19 -7.24 -18
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 8.14 6.09 0.43 0.68
Price to Tangible Book Value (P/TBV)		 8.14 6.09 0.00 10.63
Price to Revenue (P/Rev)		 559.35 6.45 9.77 22.57
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 45.47 111.31 0.44 0.64
Enterprise Value to Revenue (EV/Rev)		 501.69 5.44 9.92 19.30
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.27 0.00 0.01 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 -0.84 -0.90 -0.04 -0.05
Leverage Ratio		 1.63 1.48 1.12 1.08
Compound Leverage Factor		 1.64 1.48 1.22 1.15
Debt to Total Capital		 21.43% 0.00% 1.06% 0.00%
Short-Term Debt to Total Capital		 21.43% 0.00% 1.06% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% -0.01% -0.01%
Common Equity to Total Capital		 78.57% 100.00% 98.94% 100.01%
Debt to EBITDA		 -0.08 0.00 -0.02 0.00
Net Debt to EBITDA		 0.26 0.00 -0.01 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.12 0.00 -0.03 0.00
Net Debt to NOPAT		 0.37 0.00 -0.02 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.13 -32.25 -1.07 -0.50
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% -0.01% -0.01%
Liquidity Ratios		 - - - -
Current Ratio		 2.67 3.96 0.05 1.74
Quick Ratio		 2.62 3.50 0.04 1.69
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -6.39 -20 -12
Operating Cash Flow to CapEx		 -3,124.03% -198,845.55% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -1,429.27 -100.07
Operating Cash Flow to Interest Expense		 -208.02 0.00 -355.02 -47.60
Operating Cash Flow Less CapEx to Interest Expense		 -214.68 0.00 -350.28 -47.60
Efficiency Ratios		 - - - -
Asset Turnover		 0.01 0.71 0.08 0.03
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.08 6.85 12.45 198.27
Accounts Payable Turnover		 0.12 12.99 2.37 2.24
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 3,005.96 28.10 154.30 163.20
Cash Conversion Cycle (CCC)		 -3,005.96 -28.10 -154.30 -163.20
Capital & Investment Metrics		 - - - -
Invested Capital		 0.10 0.04 14 14
Invested Capital Turnover		 0.09 10.89 0.09 0.03
Increase / (Decrease) in Invested Capital		 0.00 -0.06 14 -0.32
Enterprise Value (EV)		 4.48 3.98 6.11 8.80
Market Capitalization		 5.00 4.72 6.02 10
Book Value per Share		 $0.06 $0.05 $5.61 $1.09
Tangible Book Value per Share		 $0.06 $0.05 ($0.52) $0.07
Total Capital		 0.78 0.77 14 15
Total Debt		 0.17 0.00 0.15 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 -0.52 -0.74 0.09 -1.49
Capital Expenditures (CapEx)		 0.04 0.00 -0.07 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.08 -0.11 -1.26 -0.83
Debt-free Net Working Capital (DFNWC)		 0.60 0.62 -1.20 0.66
Net Working Capital (NWC)		 0.43 0.62 -1.35 0.66
Net Nonoperating Expense (NNE)		 0.60 2.76 3.13 8.02
Net Nonoperating Obligations (NNO)		 -0.52 -0.74 0.09 -1.49
Total Depreciation and Amortization (D&A)		 0.00 0.02 0.73 1.72
Debt-free, Cash-free Net Working Capital to Revenue		 -910.30% -15.68% -204.35% -181.89%
Debt-free Net Working Capital to Revenue		 6,728.81% 85.35% -194.82% 144.04%
Net Working Capital to Revenue		 4,855.44% 85.35% -219.18% 144.04%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 ($8.55) ($4.84) ($2.17)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 1.07M 1.98M 10.07M
Adjusted Diluted Earnings per Share		 $0.00 ($8.55) ($4.84) ($2.17)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 1.07M 1.98M 10.07M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 5.17M 16.97M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.39 -6.45 -5.58 -13
Normalized NOPAT Margin		 -15,595.79% -882.20% -906.10% -2,768.00%
Pre Tax Income Margin		 -22,352.11% -1,259.40% -1,413.80% -4,526.87%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 -307.68 0.00 -581.90 -157.83
NOPAT to Interest Expense		 -215.37 0.00 -407.33 -102.71
EBIT Less CapEx to Interest Expense		 -314.33 0.00 -577.15 -157.83
NOPAT Less CapEx to Interest Expense		 -222.03 0.00 -402.58 -102.71
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Mangoceuticals

This table displays calculated financial ratios and metrics derived from Mangoceuticals' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 17,039,500.00 17,039,500.00 24,819,500.00 29,905,803.00 2,486,512.00 5,168,796.00 11,034,023.00 21,071,582.00 13,906,570.00 16,967,420.00 17,167,422.00
DEI Adjusted Shares Outstanding		 1,135,967.00 1,135,967.00 1,654,633.00 1,993,720.00 2,486,512.00 5,168,796.00 11,034,023.00 21,071,582.00 13,906,570.00 16,967,420.00 17,167,422.00
DEI Earnings Per Adjusted Shares Outstanding		 -3.29 -2.08 -1.45 -1.15 -0.99 -0.99 -0.49 -0.38 -0.26 -0.22 -0.09
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 112.56% 15.52% -45.60% -56.93% -48.95% 3.03% -36.83% -10.34% -37.91% -59.10%
EBITDA Growth		 -66,415.20% 7.51% 4.93% 13.81% 44.56% -87.95% -104.68% -391.37% 105.66% 29.89% 77.03%
EBIT Growth		 0.00% 7.48% 5.05% 2.30% 34.67% -104.98% -142.94% -333.36% 78.08% 29.88% 75.08%
NOPAT Growth		 0.00% 7.48% 5.39% 2.30% 34.67% -93.29% -142.94% -329.04% 78.08% 31.69% 80.39%
Net Income Growth		 0.00% 7.55% -4.70% -11.13% 24.12% -104.40% -126.48% -281.00% -42.12% 29.68% 75.76%
EPS Growth		 0.00% 0.00% -4.70% -11.13% 64.37% 25.33% 58.39% 39.47% 70.97% 80.36% 84.21%
Operating Cash Flow Growth		 -161.37% 45.19% 11.42% 31.85% 33.47% -129.51% 20.34% -6.47% 4.59% 42.35% 79.27%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% -960.80% -774.77% -3,046.83% 34.18% 51.25% 100.44% 119.31% 167.44%
Invested Capital Growth		 -63.76% 0.00% 0.00% 11,335.27% 39,164.84% 2,376.29% 45.94% 13.66% -2.31% -34.07% -37.49%
Revenue Q/Q Growth		 -0.32% -12.39% -23.79% -18.26% -21.09% 3.86% 53.80% -49.89% 12.01% -28.08% 1.32%
EBITDA Q/Q Growth		 -42.86% 7.82% 8.30% 28.63% 8.11% -212.51% -0.18% -71.33% 101.06% -3,969.61% 67.28%
EBIT Q/Q Growth		 -42.71% 7.80% 8.40% 18.93% 4.57% -189.28% -8.86% -44.61% 95.17% -825.42% 61.42%
NOPAT Q/Q Growth		 -42.71% 7.80% 8.40% 18.93% 4.57% -172.78% -8.56% -43.17% 95.12% -750.15% 66.96%
Net Income Q/Q Growth		 -42.71% 7.80% -1.00% 16.38% 2.56% -148.36% -11.91% -40.68% 63.65% -22.89% 61.42%
EPS Q/Q Growth		 -42.71% 7.80% -1.00% 16.38% -8.77% 9.68% 55.81% -21.05% 47.83% 38.89% 59.09%
Operating Cash Flow Q/Q Growth		 0.76% 41.62% -59.14% 26.08% 3.11% -101.38% 44.77% 1.21% 13.17% -21.67% 80.13%
Free Cash Flow Firm Q/Q Growth		 -25.92% 55.55% -1,851.18% 2.86% -3.83% -59.89% 59.51% 28.05% 100.93% 6,966.20% 42.51%
Invested Capital Q/Q Growth		 -69.72% -2,579.22% 1,626.25% -0.18% 3.96% 43.73% -2.15% -22.26% -10.64% -3.01% -7.22%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 58.35% 68.85% 42.77% 61.99% 76.11% 56.78% 53.51% 60.42% 50.31% 42.73% 64.31%
EBITDA Margin		 -1,048.29% -1,102.97% -1,327.16% -1,158.79% -1,349.37% -4,060.34% -2,636.54% -9,014.02% 85.22% -4,584.98% -1,480.73%
Operating Margin		 -1,050.87% -1,105.87% -1,329.13% -1,318.21% -1,594.02% -4,186.75% -3,133.98% -8,953.45% -389.72% -4,606.75% -1,502.45%
EBIT Margin		 -1,050.87% -1,105.87% -1,329.13% -1,318.21% -1,594.02% -4,440.00% -3,133.98% -9,043.49% -389.72% -5,014.65% -1,909.52%
Profit (Net Income) Margin		 -1,050.87% -1,105.87% -1,465.60% -1,499.38% -1,851.45% -4,427.47% -3,221.61% -9,043.49% -2,934.90% -5,014.65% -1,909.52%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 110.27% 113.74% 116.15% 99.72% 102.80% 100.00% 753.08% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -8,008.63% 0.00% -119.24% -102.30% -97.67% -155.31% -68.06% -202.88% -8.97% -79.88% -20.67%
ROIC Less NNEP Spread (ROIC-NNEP)		 -7,885.79% 0.00% 457.67% 34.64% 141.42% 75,921.28% -1,829.06% 1,544.45% 351.17% 887.80% -394.86%
Return on Net Nonoperating Assets (RNNOA)		 7,122.77% 0.00% -10.02% -2.64% -6.22% -16.93% -10.85% -14.20% -16.81% -6.61% -3.92%
Return on Equity (ROE)		 -885.86% 1,881.99% -129.26% -104.94% -103.89% -172.24% -78.91% -217.08% -25.78% -86.49% -24.59%
Cash Return on Invested Capital (CROIC)		 -9,510.99% 0.00% -292.15% -287.63% -278.30% -139.72% -94.41% -106.65% -88.64% -28.28% -7.74%
Operating Return on Assets (OROA)		 -748.46% -6,198.86% -151.21% -121.46% -119.57% -205.77% -89.65% -269.60% -11.30% -114.85% -34.38%
Return on Assets (ROA)		 -748.46% -6,198.86% -166.74% -138.16% -138.88% -205.19% -92.15% -269.60% -85.08% -114.85% -34.38%
Return on Common Equity (ROCE)		 -885.86% 1,881.92% -129.26% -104.70% -103.90% -172.25% -78.91% -216.84% -25.78% -86.49% -24.59%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 941.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.80 -1.66 -1.52 -1.23 -1.17 -3.20 -3.69 -5.28 -0.26 -2.19 -0.72
NOPAT Margin		 -735.61% -774.11% -930.39% -922.75% -1,115.82% -2,930.73% -2,193.78% -6,267.42% -272.80% -3,224.73% -1,051.72%
Net Nonoperating Expense Percent (NNEP)		 -122.83% 1,967.69% -576.91% -136.94% -239.09% -76,076.60% 1,761.00% -1,747.32% -360.14% -967.68% 374.20%
Return On Investment Capital (ROIC_SIMPLE)		 -232.03% 190.29% -10.83% -9.06% -8.33% -15.82% -18.59% -33.36% -1.69% -16.24% -5.75%
Cost of Revenue to Revenue		 76.81% 146.67% 176.98% 198.28% 275.41% 22.63% 384.96% 646.65% -467.15% 12.11% 636.64%
SG&A Expenses to Revenue		 850.14% 360.57% 521.38% 392.79% 811.48% 1,411.12% 740.81% 369.61% 696.47% 1,553.29% 372.46%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 1,552.01% 1,059.21% 1,252.14% 1,219.93% 2,104.18% 4,264.12% 2,849.01% 8,406.80% 2,146.61% 4,694.64% 965.81%
Earnings before Interest and Taxes (EBIT)		 -2.57 -2.37 -2.17 -1.76 -1.68 -4.85 -5.27 -7.62 -0.37 -3.40 -1.31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.56 -2.36 -2.17 -1.55 -1.42 -4.44 -4.43 -7.59 0.08 -3.11 -1.02
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 6.09 0.00 0.55 0.53 0.43 0.50 0.87 1.47 0.68 0.37 0.52
Price to Tangible Book Value (P/TBV)		 6.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.63 0.00 0.00
Price to Revenue (P/Rev)		 6.45 4.37 8.70 9.35 9.77 19.72 32.50 49.42 22.57 12.08 20.70
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 111.31 0.00 0.54 0.53 0.44 0.50 0.87 1.48 0.64 0.36 0.51
Enterprise Value to Revenue (EV/Rev)		 5.44 4.46 8.36 9.50 9.92 19.57 33.47 48.60 19.30 11.65 20.11
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 -0.09 0.01 0.01 0.01 0.00 0.03 0.01 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.90 -0.08 -0.02 -0.08 -0.04 0.00 0.01 -0.01 -0.05 -0.01 0.01
Leverage Ratio		 1.48 -0.31 1.10 1.11 1.12 1.14 1.09 1.08 1.08 1.07 1.10
Compound Leverage Factor		 1.48 -0.31 1.22 1.26 1.30 1.14 1.12 1.08 8.13 1.07 1.10
Debt to Total Capital		 0.00% -10.05% 1.34% 1.38% 1.06% 0.00% 3.02% 0.63% 0.00% 0.00% 0.36%
Short-Term Debt to Total Capital		 0.00% -10.05% 1.34% 1.38% 1.06% 0.00% 3.02% 0.63% 0.00% 0.00% 0.36%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% -0.01% -0.01% -0.01% -0.01% -0.01% -0.01% -0.01% -0.02%
Common Equity to Total Capital		 100.00% 110.04% 98.66% 98.37% 98.94% 100.01% 96.98% 99.38% 100.01% 100.01% 99.66%
Debt to EBITDA		 0.00 -0.01 -0.02 -0.02 -0.02 0.00 -0.05 -0.01 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 -0.01 0.03 -0.01 -0.01 0.00 -0.04 0.02 0.00 0.00 0.01
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.01 -0.03 -0.03 -0.03 0.00 -0.06 -0.01 0.00 0.00 -0.01
Net Debt to NOPAT		 0.00 -0.01 0.05 -0.02 -0.02 0.00 -0.05 0.03 0.00 0.00 0.02
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -11.36 -88.97 1.27 0.87 0.29 1.57 3.27 12.50 3.40 -1.98 -2.49
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.23% -0.01% -0.01% 0.00% 0.11% -0.01% -0.01% -0.01%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.96 0.07 0.38 0.07 0.05 0.12 0.07 0.74 1.74 0.29 0.18
Quick Ratio		 3.50 0.01 0.36 0.05 0.04 0.05 0.06 0.60 1.69 0.26 0.16
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.73 -0.77 -15 -15 -15 -24 -9.90 -7.12 0.07 4.69 6.68
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -67.56 -60.49 0.00 0.00 -67.21 -93.93 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -7.08 -4.83 0.00 0.00 -8.53 -16.36 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -7.08 -4.83 0.00 0.00 -8.53 -16.36 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.71 5.61 0.11 0.09 0.08 0.05 0.03 0.03 0.03 0.02 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 60.64 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 6.85 0.00 0.00 14.32 12.45 11.06 183.74 182.74 198.27 202.23 175.32
Accounts Payable Turnover		 12.99 0.00 0.00 2.50 2.37 0.78 2.49 3.33 2.24 1.62 1.42
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 6.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 28.10 0.00 0.00 145.84 154.30 468.78 146.43 109.59 163.20 224.90 257.14
Cash Conversion Cycle (CCC)		 -28.10 0.00 0.00 -139.82 -154.30 -468.78 -146.43 -109.59 -163.20 -224.90 -257.14
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.04 -0.89 14 14 14 20 20 15 14 13 12
Invested Capital Turnover		 10.89 -1.91 0.13 0.11 0.09 0.05 0.03 0.03 0.03 0.02 0.02
Increase / (Decrease) in Invested Capital		 -0.06 -0.89 14 13 14 21 6.21 1.84 -0.32 -6.87 -7.40
Enterprise Value (EV)		 3.98 3.77 7.24 7.17 6.11 10 17 23 8.80 4.83 6.34
Market Capitalization		 4.72 3.70 7.55 7.06 6.02 10 17 23 10 5.01 6.52
Book Value per Share		 $0.05 ($0.06) $0.56 $0.45 $5.61 $3.92 $1.74 $1.49 $1.09 $0.97 $0.73
Tangible Book Value per Share		 $0.05 ($0.06) ($0.03) ($0.04) ($0.52) ($0.25) ($0.13) ($0.02) $0.07 ($0.03) ($0.07)
Total Capital		 0.77 -0.87 14 14 14 20 20 16 15 13 13
Total Debt		 0.00 0.09 0.19 0.19 0.15 0.00 0.60 0.10 0.00 0.00 0.04
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.74 0.07 -0.30 0.11 0.09 -0.08 0.50 -0.38 -1.49 -0.17 -0.18
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.11 -1.05 -1.16 -1.17 -1.26 -1.40 -0.98 -0.59 -0.83 -0.70 -1.34
Debt-free Net Working Capital (DFNWC)		 0.62 -1.03 -0.67 -1.10 -1.20 -1.33 -0.88 -0.11 0.66 -0.53 -1.11
Net Working Capital (NWC)		 0.62 -1.12 -0.86 -1.29 -1.35 -1.33 -1.48 -0.21 0.66 -0.53 -1.15
Net Nonoperating Expense (NNE)		 0.77 0.71 0.87 0.77 0.77 1.64 1.73 2.34 2.51 1.21 0.59
Net Nonoperating Obligations (NNO)		 -0.74 0.07 -0.30 0.11 0.09 -0.08 0.50 -0.38 -1.49 -0.17 -0.18
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.00 0.21 0.26 0.41 0.84 0.02 0.45 0.29 0.29
Debt-free, Cash-free Net Working Capital to Revenue		 -15.68% -124.30% -134.22% -155.46% -204.35% -274.52% -190.69% -125.79% -181.89% -168.77% -423.86%
Debt-free Net Working Capital to Revenue		 85.35% -122.49% -77.67% -145.67% -194.82% -259.56% -171.11% -22.71% 144.04% -126.67% -351.31%
Net Working Capital to Revenue		 85.35% -132.85% -99.30% -170.51% -219.18% -259.56% -287.38% -44.13% 144.04% -126.67% -365.57%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($52.20) $0.00 ($1.35) ($0.99) ($1.24) ($1.29) ($0.57) ($0.69) ($0.36) ($0.22) ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 71.61K 1.65M 1.74M 2.01M 1.98M 4.59M 0.00 11.52M 10.07M 16.48M 17.12M
Adjusted Diluted Earnings per Share		 ($52.20) $0.00 ($1.35) ($0.99) ($1.24) ($1.29) ($0.57) ($0.69) ($0.36) ($0.22) ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding		 71.61K 1.65M 1.74M 2.01M 1.98M 4.59M 9.98M 11.52M 10.07M 16.48M 17.12M
Adjusted Basic & Diluted Earnings per Share		 ($52.20) $0.00 $0.00 $0.00 ($1.24) $0.00 $0.00 $0.00 ($0.36) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 1.65M 1.99M 2.49M 5.17M 11.03M 10.54M 13.91M 16.97M 17.17M 21.57M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.80 -1.66 -1.52 -1.23 -1.17 -3.20 -3.69 -5.28 -0.26 -2.19 -0.72
Normalized NOPAT Margin		 -735.61% -774.11% -930.39% -922.75% -1,115.82% -2,930.73% -2,193.78% -6,267.42% -272.80% -3,224.73% -1,051.72%
Pre Tax Income Margin		 -1,050.87% -1,105.87% -1,465.60% -1,499.38% -1,851.45% -4,427.47% -3,221.61% -9,043.49% -2,934.90% -5,014.65% -1,909.52%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -9.74 -7.28 0.00 0.00 -35.76 -100.45 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -6.82 -5.09 0.00 0.00 -25.03 -69.61 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -9.74 -7.28 0.00 0.00 -35.76 -100.45 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -6.82 -5.09 0.00 0.00 -25.03 -69.61 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Mangoceuticals’ Q2 2026 financial statements show some sequential improvement in losses and operating cash burn, but the company remains dependent on external financing and has limited liquidity. Revenue was $68,757, essentially flat with $67,864 in Q1 2026 but down sharply from $168,109 in Q2 2025 and $245,160 in Q3 2023.

  • Net loss narrowed materially. Consolidated net loss improved to $1.31 million in Q2 2026 from $3.40 million in Q1 2026 and $5.42 million in Q2 2025. The loss attributable to common shareholders declined to $1.61 million, or $0.09 per share, compared with $3.70 million, or $0.22 per share, in Q1.
  • Operating cash burn improved. Cash used in operating activities declined to $260,506 in Q2 2026 from $1.31 million in Q1 2026 and $1.26 million in Q2 2025. This was the company’s lowest quarterly operating cash outflow in the supplied period.
  • Cash increased modestly during the quarter. Cash and equivalents rose from $174,562 at March 31, 2026, to $228,688 at June 30, 2026. Financing proceeds, including $272,000 from common equity issuance, more than offset operating cash use.
  • Current liabilities declined over the longer term. Total current liabilities of $1.40 million in Q2 2026 were below the $1.60 million reported in Q2 2025 and the $1.69 million reported in Q2 2024, although liabilities increased sequentially from $737,606 in Q1 2026.
  • Revenue has stabilized at a low level recently. Q2 2026 revenue edged up 1.3% from Q1 2026, but the company’s revenue remains well below the $109,306 reported in Q1 2025 and the $244,374 reported in Q4 2023. Sustained growth will be important for improving operating leverage.
  • Amortization remains a significant noncash expense. Q2 2026 included $294,574 of amortization, which helped reduce the gap between net loss and operating cash flow. Investors should distinguish this noncash benefit from underlying improvements in the company’s cash-generating operations.
  • Liquidity remains weak. The company held only $228,688 in cash against $1.40 million of current liabilities, producing a current ratio of approximately 0.18 based on reported figures. Cash alone is insufficient to cover near-term obligations without additional operating cash generation or financing.
  • Mangoceuticals continues to consume cash from operations. Operating cash flow has been negative in every supplied quarter, including approximately $1.31 million in Q1 2026 and $1.08 million in Q4 2025. The improved Q2 result does not yet establish a sustainable positive cash-flow trend.
  • Profitability has not been established. Gross profit remained small relative to operating expenses, while Q2 operating expenses totaled $664,062. The company reported a $1.03 million operating loss and a $1.31 million pretax loss during the quarter.
  • Shareholder dilution and accumulated losses are substantial. Weighted-average basic shares rose to 17.1 million in Q2 2026 from 4.6 million in Q1 2024, while retained earnings showed a deficit of $45.4 million. Common equity issuance has repeatedly supported cash balances, creating potential dilution risk for existing shareholders.

Overall, Q2 2026 was better than the preceding quarter on a loss and cash-burn basis, but the improvement came from a very low revenue base and did not eliminate the company’s financing needs. Investors should focus on whether Mangoceuticals can produce consistent revenue growth, reduce operating expenses and move operating cash flow toward breakeven before its limited cash balance becomes a more immediate concern.

11/13/26 10:13 AM ETAI Generated. May Contain Errors.

Mangoceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Mangoceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Mangoceuticals' net income appears to be on a downward trend, with a most recent value of -$20.64 million in 2025, falling from -$2.00 million in 2022. The previous period was -$8.71 million in 2024. See Mangoceuticals' forecast for analyst expectations on what's next for the company.

Mangoceuticals' total operating income in 2025 was -$18.03 million, based on the following breakdown:
  • Total Gross Profit: $250.39 thousand
  • Total Operating Expenses: $18.21 million

Over the last 3 years, Mangoceuticals' total revenue changed from $8.94 thousand in 2022 to $456.02 thousand in 2025, a change of 5,001.5%.

In the past 11 quarters, Mangoceuticals' cash and equivalents has ranged from $15.31 thousand in Q1 2024 to $1.24 million in Q3 2023, and is currently $228.69 thousand as of their latest financial filing in Q2 2026.

Mangoceuticals had total debt of $0.00 at the end of 2025, a 100.0% decrease from 2024, and a 100.0% decrease since 2022.

Over the last 3 years, Mangoceuticals' book value per share changed from 0.06 in 2022 to 1.09 in 2025, a change of 1,820.9%.


Related Companies

Financial statements for NASDAQ:MGRX last updated on 8/19/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...
Crypto 101 Media | Sponsoredtc pixel